BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is an American biotechnology company headquartered in Durham, North Carolina, with a Discovery Center of Excellence in Birmingham, Alabama. Founded in 1986, the company is dedicated to the research, development, and commercialization of novel small-molecule drugs for patients with rare and serious diseases. Its mission is to discover, develop, and deliver treatments that can significantly impact the lives of patients who currently have limited or no therapeutic options, leveraging expertise in enzyme inhibition and structure-guided drug design.

The company's primary commercial product is ORLADEYO® (berotralstat), an oral, once-daily plasma kallikrein inhibitor approved for the prevention of hereditary angioedema (HAE) attacks. BioCryst also markets peramivir injection (Rapivab, Rapiacta, Peramiflu) for influenza. Its pipeline includes investigational therapies such as BCX17725 for Netherton syndrome, Avoralstat for diabetic macular edema, and Navenibart for HAE, focusing on rare genetic diseases, the complement system, and hematology.

In recent news, BioCryst completed the acquisition of Astria Therapeutics on January 23, 2026, a strategic move aimed at expanding its leadership in hereditary angioedema. The company reported strong financial performance for 2025, with ORLADEYO net revenue reaching $601 million, exceeding prior guidance. This growth followed the divestiture of its European ORLADEYO business in 2025, which helped retire debt and improve financial flexibility. BioCryst plans to increase research and development investments in 2026 to support ongoing trials and the launch of new products, including ORLADEYO pellets for pediatric use. Jon P. Stonehouse serves as President and CEO, and Sandeep M. Menon was appointed Chief Research and Development Officer in April 2026.